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Abstract. Background: Hypomethylating agents, such as
azacitidine and decitabine, now constitute one of the
mainstays of myelodysplastic syndrome (MDS) treatment. In
recent years, novel recurrent mutations in multiple genes
encoding RNA spliceosomal machinery (SRSF2, U2AF1,
ZRSR2, SF3B1) were revealed. However, the clinical impact
of these mutations on the outcomes of treatment of MDS
patients with hypomethylating agents has not been described.
Patients and Methods: A total of 58 de novo MDS patients
were included in the study who had received first-line
decitabine treatment. Polymerase chain reaction (PCR)
followed by direct sequencing analyses was performed for the
spliceosomal machinery genes including SRSF2, U2AF1 and
ZRSR2. Results: In the present analysis of 58 Korean MDS
patients, mutations in the splicing machinery genes SRSF2,
U2AF1 and ZRSR2 were detected in 5 (8.6%), 10 (17.2%) and
6 (10.3%) patients, respectively, and the incidence of SRSF2
mutation was lower than those of previous series. The overall
response rates (ORRs) including complete remission (CR),
partial response (PR), and marrow CR (mCR) were 42.9% in
the spliceosome wild-type (WT) group and 46.7% in the
spliceosome-mutated group (p>0.999). The median OS was
22.0 months in the spliceosome-WT group and 15.9 months in
the spliceosome-mutated group (p=0.267) Conclusion: This
study firstly reports the impact of mutations of the
spliceosomal machinery genes on the outcomes of decitabine
treatment in MDS. The mutational status of the SRSF2,
U2AF1 and ZRSR2 did not affect the response rate or survival
in MDS patients who had received first-line decitabine
treatment. Further studies are needed to confirm the
prognostic relevance of spliceosome mutations to the clinical
outcomes of treatment with hypomethylating agents.
The myelodysplastic syndromes (MDSs) are a group of clonal
disorders of the hematopoietic system characterized by
ineffective hematopoiesis, peripheral cytopenia and an
increased risk of acute myeloid leukemia (AML).
Hematopoietic stem cell transplantation (HSCT) is the curative
treatment modality but several issues regarding the use of
HSCT to treat MDS remain unresolved, such as treatment-
related mortality, graft-versus-host disease and the feasibility
in the treatment of elderly and frail patients. Thus,
hypomethylating agents, such as the DNA methyltransferase
inhibitors azacitidine and decitabine now constitute one of the
mainstays of MDS treatment. These drugs have favorable
response rates and survival benefit in patients with MDS (1-6). 
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In recent years, the use of next-generation sequencing in
patients with MDS has revealed novel recurrent mutations in
multiple genes encoding the epigenetic machinery (TET2,
DNMT3A, ASXL1, EZH2, IDH1/2) (7-12) and RNA
spliceosomal machinery (SRSF2, U2AF1, ZRSR2, SF3B1) (13-
17). Of note, the RNA-splicing process, whereby non-coding
sequences called introns are removed from pre-mRNA, is
crucial for gene expression and genetic diversity (18, 19). The
detailed splicing consequences are complex and the exact
mechanism to explain how somatic mutations in spliceosomal
machinery genes can affect the pathogenesis of MDS has not
been defined. A number of studies have tried to investigate the
clinical impact of mutations in spliceosomal machinery genes
in MDS but they failed to demonstrate a consistent prognostic
relevance. For example, SRSF2 and U2AF1 mutations are
associated with unfavorable clinical outcomes and a high risk
of transformation to AML in some (14, 20) but not in all (21)
studies. Some studies have suggested a positive prognostic
impact of SF3B1 mutations in MDS (17, 22), while other
studies have reported no prognostic value of these mutations
(23, 24). The clinical impact of these mutations on the
outcomes of treatment of MDS patients with hypomethylating
agents has not been described.
In the era of use of hypomethylating agents in the treatment
of MDS, we aimed to investigate the prevalence and
prognostic impact of mutations in the spliceosome machinery
genes SRSF2, U2AF1 and ZRSR2 on the outcomes of first-line
decitabine treatment in patients with MDS.
Patients and Methods
Patients. Between June 2008 and December 2011, a total of 58 de
novo MDS patients were included in the study who had received 1st-
line decitabine treatment and had adequate genomic DNA from pre-
treated bone marrow samples. The patients were diagnosed with
MDS according to French-American-British (FAB) classification at
the Samsung Medical Center. Among them, the 48 patients fulfilled
the criteria of MDS according to World Health Organization (WHO)
2008 classification. Clinical information was obtained by reviewing
the medical record of each patient. Reviewed clinical parameters
were as follows: age, sex, complete blood count, bone marrow blast
count, cytogenetics, International Prognostic Scoring System (IPSS)
risk category, Revised International Prognostic Scoring System
(IPSS-R) risk category, response to decitabine, leukemia-free survival
(LFS) and overall survival (OS). All patients signed an informed
consent form for sample collection. This study was approved by the
Institutional Review Board of the Samsung Medical Center, Seoul,
Korea, and the protocol protected the confidentiality of all patients. 
Gene mutation analysis. Genomic DNA was extracted from bone
marrow (BM) aspirate samples using the Wizard Genomic DNA
Purification Kit (Promega, Madison, WI, USA) according to
manufacturer’s recommendation. Polymerase chain reaction (PCR)
followed by direct sequencing analyses was performed for the
following genes including SRSF2 (targeted, exon 1), U2AF1
(targeted, exon 3 and exon 7), ZRSR2 (all exons), TET2 (targeted,
exon 3~11), TP53 (targeted, exon 2~11), NRAS (targeted, exon 2
and exon 3). Sequencing analyses were performed by the BigDye
Terminator Cycle Sequencing Ready Reaction kit on an ABI Prism
3100 Genetic Analyzer (Applied Biosystems, Foster City,
California, USA). Mutations were detected by using the Sequencher
program (Gene Codes Corp., Ann Arbor, MI, USA).
Treatment and responses. All patients received decitabine as 1st-line
treatment according to 5-day dosing regimen approved by the US
Food and Drug Administration (FDA) (20 mg/m2 per day
intravenously, for 5 days every 4 weeks). BM examination was
performed before the first administration of decitabine and responses
were evaluated every 2 or 3 cycles. Overall responses were defined
according to the modified International Working Group (IWG) 2006
criteria for MDS (25), including complete remission (CR), partial
response (PR), marrow CR (mCR) or stable disease (SD) with
hematologic improvement (HI). Responders were to continue
treatment until disease progression or unacceptable toxicity.
Statistical analysis. Descriptive statistics were reported as
proportions and medians. Inter-group comparisons were performed
with Fisher’s exact test for categorical variables and the Mann-
Whitney test for age. LFS was calculated from the first day of
decitabine treatment to the day of diagnosis with leukemic
transformation, death as a result of any cause or last date of follow-
up. Overall survival (OS) was calculated from the first day of
decitabine treatment to death or to the last date of follow-up.
Survival curves were generated by Kaplan-Meier methods and
survival was compared using the log-rank test. Univariate analysis
was performed using Cox regression analysis. Statistical analyses
were performed using the statistical software package IBM PASW,
version 18.0 (SPSS Inc., Chicago, IL, USA). 
Results
Patients’ characteristics. The baseline characteristics of the
58 patients are shown in Table I. The median age of the
patients was 67 years (range=26-89) and the male:female
ratio was 3.8:1.0. Forty-nine patients had MDS and 9
patients had chronic myelomonocytic leukemia (CMML).
The International Prognostic Scoring System (IPSS) risk
category (26) was low in 1 patient (1.7%), intermediate-1 in
33 patients (56.9%), intermediate-2 in 18 patients (31.0%)
and high in 6 patients (10.3%). We categorized the patients
into two groups. Patients having no spliceosomal machinery
gene mutations were classified into the spliceosome wild-
type (WT) group (n=38, 65.5%); patients having ≥1 mutation
in the spliceosomal machinery genes SRSF2, U2AF1 and
ZRSR2 were classified into the spliceosome-mutated group
(n=20, 34.5%). In this small population of patients, the
baseline clinical characteristics, demographics, cytogenetic
risk group, IPSS score and IPSS-R risk score did not differ
significantly between the two groups (Table I).
Mutation status of spliceosomal machinery genes. As shown in
Table I, mutations in the splicing machinery genes SRSF2,
U2AF1 and ZRSR2 were detected in 5 (8.6%), 10 (17.2%) and
ANTICANCER RESEARCH 35: 3081-3090 (2015)
3082
6 (10.3%) patients, respectively. The genomic changes and
mutation patterns of 20 patients in the spliceosome-mutated
group are summarized in Table II. There were 16 missense
mutations, 3 frameshift mutations and 2 splicing mutations. We
identified only 1 patient (patient #15) with concomitant U2AF1
and ZRSR2 mutations (Table II). Mutations in the TET2, TP53
and NRAS genes were found in 5 (8.6%), 7 (12.1%) and 3
(5.2%) patients, respectively. TP53 and NRAS mutations were
found only in the spliceosome WT group (Table I).
Impact of spliceosome mutations on the efficacy outcomes of
decitabine. The efficacy outcomes of decitabine according to
the spliceosome mutations are summarized in Table III. The
median number of cycles of decitabine treatment was 4 in
both the spliceosome-WT and spliceosome-mutated groups.
The overall response rates (ORRs) including CR, PR and
mCR were 42.9% in the spliceosome WT group and 46.7%
in the spliceosome-mutated group (p>0.999). The ORRs,
including CR, PR, mCR and SD with hematological
Hong et al: SRSF2, U2AF1 and ZRSR2 on the Response to Decitabine in MDS
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Table I. Baseline characteristics of study participants. 
Total Spliceosome WT Spliceosome p-Value
(n=58) (n=38) Mutated (n=20)
Age, years 0.777
Median (Range) 67 (26-89) 67 (26-83) 66 (27-89)
Gender, n(%) 0.187
Male 46 (79.3) 28 (73.7) 18 (90.0)
Female 12 (20.7) 10 (26.3) 2 (10.0)
Lab data, n(%)
Neutropenia (ANC < 1800) 41 (70.7) 26 (68.4) 15 (75.0) 0.764
Anemia (Hb <10 g/dl) 42 (72.4) 27 (71.1) 15 (75.0) >0.999
Thrombocytopenia (PLT <100k) 36 (62.1) 24 (63.2) 12 (60.0) >0.999
FAB subtype, n(%) 0.528
RA/RARS 20 (34.5) 15 (39.5) 5 (25.0)
RAEB/RAEBT 29 (50.0) 18 (47.4) 11 (55.0)
CMML 9 (15.5) 5 (13.2) 4 (20.0)
Karyotype risk, n(%) 0.177
Good (0) 28 (48.3) 16 (42.1) 12 (60.0)
Intermediate 16 (27.6) 10 (26.3) 6 (30.0)
Poor (1) 14 (24.1) 12 (31.6) 2 (3.4)
IPSS risk, n(%) 0.354
Low 1 (1.7) 1 (2.6) 0 (0.0)
Intermediate-1 33 (56.9) 23 (60.5) 10 (50.0)
Intermediate-2 18 (31.0) 9 (23.7) 9 (45.0)
High 6 (10.3) 5 (13.2) 1 (5.0)
IPSS-R risk, n(%) 0.962
Very low 1 (1.7) 1 (2.6) 0 (0.0)
Low 10 (17.2) 7 (18.4) 3 (15.0)
Intermediate 20 (34.5) 13 (34.2) 7 (35.0)
High 12 (20.7) 7 (18.4) 5 (25.0)
Very high 15 (25.9) 10 (26.3) 5 (25.0)
BM blast, n(%) >0.999
<5% 27 (46.6) 19 (50.0) 8 (40.0)
5-9% 15 (25.9) 12 (31.6) 3 (15.0)
10-19% 16 (27.6) 7 (18.4) 9 (45.0)
Mutations, n(%)
SRSF2 5 (8.6) 0 (0.0) 5 (25.0) 0.003
U2AF1 10 (17.2) 0 (0.0) 10 (50.0) <0.001
ZRSR2 6 (10.3) 0 (0.0) 6 (30.0) 0.001
TET2 5 (8.6) 2 (5.3) 3 (15.0) 0.328
TP53 7 (12.1) 7 (18.4) 0 (0.0) 0.083
NRAS 3 (5.2) 3 (7.9) 0 (0.0) 0.544
WT; Wild type, ANC; absolute neutrophile count, Hb; hemoglobin, PLT; platelet, RA; refractory anemia, RARS; refractory anemia with ringed
sideroblast, RAET; refractory anemia with excess blast, RAEBT; refractory anemia with excess blast in transformation, CMML; chronic
myelomonocytic leukemia, FAB; French–American–British, IPSS; International Prognostic Scoring System, IPSS-R; Revised International Prognostic
Scoring System, BM; bone marrow.
improvement (SD with HI), did not differ significantly
between the groups (71.4% vs. 60.0%, p=0.507).
At a median follow-up of 40 months, 16 (27.6%) leukemic
transformations and 49 (84.5%) deaths were documented. The
median LFS and OS were 17.9 months and 18.8 months,
respectively (Figure 1A). In patients classified according to
their IPSS scores, patients with low and intermediate-1 risk had
significantly better OS compared to patients with intermediate-
2 and high risk (p=0.014) (Figure 1B). The median LFS did
not significantly differ between the spliceosome-WT group and
spliceosome-mutated group (20.9 months vs. 15.9 months,
respectively; p=0.251). The median OS was 22.0 months in the
spliceosome-WT group and 15.9 months in the spliceosome-
mutated group (p=0.267) (Figure 1C). The 1-year expected OS
rate did not differ significantly between the two groups (71.0%
vs. 66.7%, p=0.929). No survival differences were observed in
relation to the SRSF2, U2AF1 and ZRSR2 mutational status
(Figure 1D, E, F). Sub-group analysis of patients with low,
intermediate-1 and intermediate-2 risk (excluding patients with
high risk) showed a trend of poor LFS and OS of spliceosome-
mutated group compared to spliceosome-WT group but failed
to show statistical significance (LFS=22.0 months vs. 15,9
months, p=0.20 and OS=15.9 months vs. 24.1 months, p=0.22)
(Figure 2 A,B).
Table IV shows the results of univariate analysis of LFS
and OS. IPSS risk (intermediate-2 or high) and IPSS-R risk
(high or very high) were significant negative prognostic
factors for LFS. The respective hazard ratios (HRs) were as
follows: for LFS, HR=2.4 (95% confidence interval
(CI)=1.3-4.4, p=0.016) and 2.1 (95% CI=1.1–3.9; p=0.026);
for OS, HR=2.2 (95% CI=1.2-4.3; p=0.017) and HR=1.9
(95% CI=1.0-3.6; p=0.044). However, the spliceosomal
mutations and respective mutational status (SRSF2, U2AF1,
ZRSR2, TET2, TP53 and NRAS) did not affect OS. 
Discussion
In this analysis of 58 Korean MDS patients, the incidence of
SRSF2 mutation (8.6%) was lower than those of previous
series (12.4-14.6%) and the mutational status of the
spliceosome genes SRSF2, U2AF1 and ZRSR2 did not affect
the response rate or survival in MDS patients who had
received first-line decitabine treatment (20, 21).
Decitabine (5-aza-2’-deoxycytidine) and azacitidine (5-
azacytidine) allow for treatment of elderly and frail MDS
patients, achieve hematological improvement and transfusion
independency and have overall survival benefit (1-6). In 2006,
the US Food and Drug Administration approved these
hypomethylating agents for the treatment of all subtypes of
MDS. Hypomethylating agents now constitute to offer an
essential option in the treatment of MDS. Itzykson et al.
demonstrated that previous treatment with low-dose cytosine
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Table II. Characteristics of 20 patients with mutations in spliceosomal machinery genes.
Gender/Age Diagnosis Karyotype BM blast Mutated gene Genomic change Mutation type
1 M/71 RAEB 46,XY 7.29 SRSF2 c.284C>G (p.Pro95Arg) Missense mutation
2 M/64 RAEB 46,XY 8.06 SRSF2 c.284C>A (p.Pro95His) Missense mutation
3 M/74 RAEB 46,XY 8.2 SRSF2 c.284C>A (p.Pro95His) Missense mutation
4 M/64 RAEB 46,XY 16.08 SRSF2 c.284C>A (p.Pro95His) Missense mutation
5 M/80 RAEB 46,XY 14.87 SRSF2 c.284C>A (p.Pro95His) Missense mutation
6 M/65 RAEB 46,XY 3.64 U2AF1 c.470A>C (p.Gln157Pro) Missense mutation
7 M/31 RARS 46,XY,i(21)(q10)[30] 3.72 U2AF1 c.101C>A (p.Ser34Tyr) Missense mutation
8 M/27 RARS 47,XY,+8[6]/46,XY[14] 0.84 U2AF1 c.101C>T (p.Ser34Phe) Missense mutation
9 M/57 CMML 46,XY,del(7)(q22)[9] 2.13 U2AF1 c.470A>G (p.Gln157Arg) Missense mutation
10 M/68 RAEB 45,XY,-7[20] 11.07 U2AF1 c.470A>G (p.Gln157Arg) Missense mutation
11 M/71 CMML 46,XX 12 U2AF1 c.101C>A (p.Ser34Tyr) Missense mutation
12 M/89 RA 47,XY,+8[4]/46,XY[7] 0.94 U2AF1 c.101C>A (p.Ser34Tyr) Missense mutation
13 M/67 RAEB 46,XX 1.23 U2AF1 c.101C>A (p.Ser34Tyr) Missense mutation
14 M/28 CMML 47,XY,+8,i(20)(q10)[20] 12 U2AF1 c.101C>A (p.Ser34Tyr) Missense mutation
15 M/62 RA 46,XY,der(1)?t(1;3)(p34.3;q21), 1.85 U2AF1 c.101C>T (p.Ser34Phe)  Missense mutation
dup(1)(p34.1p36.1)[20] ZRSR2 c.1294G>C (p.Asp432His) Missense mutation
16 M/67 RAEB 46,XY 13.62 ZRSR2 c.772-3T>G Splicing mutation
17 M/72 CMML 46,XY 0.94 ZRSR2 c.325delG (p.Glu109Asnfs*56) Frameshift mutation
18 M/73 RAEB 46,XY 11.01 ZRSR2 c.45-4C>A Splicing mutation
19 M/53 RAEB 46,XY 14 ZRSR2 c.1343_1344insGAGCCG Frameshift mutation
20 M/48 RAEB 46,XY,inv(3)(q21q26.2) 12 ZRSR2 c.1207delA (p.Arg403Glyfs*114) Frameshift mutation
[13]/46,XY[7]
BM; Bone marrow, RA; refractory anemia, RARS; refractory anemia with ringed sideroblast, RAET; refractory anemia with excess blast, RAEBT;
refractory anemia with excess blast in transformation, CMML; chronic myelomonocytic leukemia.
arabinoside, bone marrow blast percentage >15%, circulating
blasts, complex karyotype and red blood cell transfusion
dependency were significant clinical parameters associated with
lower response rates and/or worse OS in MDS patients treated
with decitabine (27). Follo et al. suggested phosphoinositide-
phospholipase C beta 1 hypomethylation as a favorable
predictive factor to azacitidine treatment (28). In this era of novel
mutations in MDS, the identification of subgroups who benefit
most to hypomethylating agents is needed in terms of mutational
status. However, there are few data on the molecular predictors
of the response to hypomethylating agents in MDS patients.
Recently identified novel recurrent mutations in epigenetic
machinery (TET2, DNMT3A, ASXL1, EZH2, IDH1/2) (7-12)
and RNA spliceosomal machinery (SRSF2, U2AF1, ZRSR2,
SF3B1) (13-17) have led to considerable progress in
understanding the molecular mechanisms involved in the
development of MDS. However, the precise impact of these
mutations and their accuracy as molecular predictors of clinical
outcomes have not been established fully and remain
controversial (14, 17, 20-24). Clinical data on the impact of
these mutations on the response to hypomethylating agents are
also scarce. One French report, by Itzykson et al., showed a
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Table III. Efficacy outcomes of decitabine according to spliceosome mutations.
Total Spliceosome Spliceosome p-Value
(n=58) WT (n=38) Mutated (n=20)
Response, n(%) (n=46)# 0.549
CR 6 (14.0) 4 (14.3) 2 (13.3)
CRm 10 (23.3) 5 (17.9) 5 (33.3)
PR 3 (7.0) 3 (10.7) 0 (0.0)
SD with HI 10 (23.3) 8 (28.6) 2 (23.3)
SD without HI 8 (18.6) 4 (14.3) 4 (26.7)
Progression 6 (14.6) 4 (14.3) 2 (13.3)
Overall response, n(%) (n=46)#
CR, PR, CRm 19 (44.2) 12 (42.9) 7 (46.7) >0.999
CR, PR, CRm, SD with HI 29 (67.4) 20 (71.4) 9 (60.0) 0.507
Leukemic transformation, n(%) 16 (27.6) 8 (21.1) 8 (40.0) 0.138
Suvival, months (n=46) *
LFS, median (95% CI) 17.9 (10.5-25.4) 20.9 (12.9-28.9) 15.9 (5.5-26.4) 0.251
OS, median (95% CI) 18.8 (10.9-26.7) 22.0 (12.8-31.3) 15.9 (3.4-28.4) 0.267
1 year expected OS rate 63.0% 71.0% 66.7%
Decitabine cycles, n(range) 4 (1-25) 4 (1-25) 4 (1-17)
WT; Wild type, CR; complete remission, CRm; marrow CR, PR; partial remission, SD; stable disease, HI; hematological improvement, LFS;
leukemia-free survival, OS; overall survival. #12 patients who have not available clinical data for response evaluation were excluded. *12 patients
who received salvage therapy of allogeneic stem cell transplantation were excluded.
Table IV. Univariate analysis for leukemia-free survival and overall survival.
Leukemia-free survival Overall survival
Variables HR (95% CI) p-Value HR (95% CI) p-Value
Age > 60 1.3 (0.5-3.0) 0.605 1.5 (0.6-3.6) 0.352
Male gender 1.4 (0.7-3.0) 0.333 0.7 (0.3-1.4) 0.679
IPSS risk (Intermediate-2, high) 2.4 (1.2-4.3) 0.016 2.2 (1.2-4.3) 0.017
IPSS-R risk (high, very high) 2.1 (1.1-3.9) 0.026 1.9 (1.0-3.6) 0.044
Any spliceosomal mutations (SRSF2, U2AF1, ZRSR2) 1.5 (0.8-2.8) 0.254 1.4 (0.8-2.7) 0.270
SRSF2 mutation 1.1 (0.4-2.8) 0.843 1.1 (0.4-2.7) 0.901
U2AF1 mutation 1.4 (0.6-3.2) 0.418 1.4 (0.6-3.1) 0.454
ZRSR2 mutation 1.1 (0.4-3.2) 0.821 1.1 (0.4-3.1) 0.872
TET2 mutation 0.6 (0.2-1.7) 0.352 0.6 (0.2-1.8) 0.372
TP53 mutation 1.4 (0.6-3.2) 0.431 1.6 (0.7-3.6) 0.268
NRAS mutation 1.6 (0.4-6.5) 0.549 1.6 (0.4-6.7) 0.536
HR; Hazard ratio, CI, confidence interval; IPSS; International Prognostic Scoring System, IPSS-R; Revised International Prognostic Scoring System.
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Figure 1. Kaplan-Meier curves for overall survival (A) all patients, (B) IPSS risk, (C) any mutations of spliceosomal machinery, (D) SRSF2 mutation,
(E) U2AF1 mutation, (F) ZRSR2 mutation.
correlation between the epigenetic machinery (TET2) mutation
and poor clinical response to azacitidine, even though there was
no impact on OS (29). The functional consequences of these
mutations on spliceosomal machinery genes are not well
defined. Some reports have suggested that these mutations
result in increased or decreased RNA splicing, whereas others
have suggested that these genes down-regulate key gene
networks, including the core mitochondrial pathway (13, 16,
17). Recent reports notably suggest that mutations on
spliceosomal machinery genes probably play a role in the MDS
initiation but not disease progression and evolution to AML
(21, 30, 31). Actually, among previous studies, that showed
prognostic impact of SRSF2 mutations in MDS, SRSF2
mutation showed more prominent prognostic impact in patients
with lower IPSS risk groups. (20, 21) In this study, we also
performed a subgroup analysis excluding the patients with high
IPSS risk group. The results showed a trend of poor LFS and
OS of spliceosome-mutated group compared to spliceosome
WT group but failed to show statistical significance as shown
in Figure 2A and B. Considering previous findings and our
results, we suggest that the prognostic impact of spliceosome
mutations on the clinical outcomes of decitabine treatment
needs to be investigated further in terms of MDS risk groups.
Previous studies on the prognostic impact of spliceosomal
mutations in MDS have included heterogeneous populations
in terms of treatment modality, such as the use of
hypomethylating agents and previous treatment history. The
clinical impact of spliceosomal machinery genes on the
response to hypomethylating agents has not been explored
systemically. Our findings are based on a relatively small
number of patients and, therefore, need to be interpreted
cautiously. Nevertheless, this study has several strengths. To
our knowledge, this is the first study to evaluate the
relationship between spliceosomal machinery gene mutations
and response to hypomethylating agents in MDS patients.
We included patients who had received decitabine treatment
as the only first-line treatment. Thus, this study included a
relatively homogeneous group of patients in terms of their
MDS duration and previous treatment history.
In summary, this study demonstrated that the spliceosome
mutations SRSF2, U2AF1 and ZRSR2 did not affect the
clinical outcomes in response to decitabine treatment. In the
era of the use of hypomethylating agents, prospective studies
with larger populations are needed to confirm the prognostic
relevance of spliceosome mutations to the clinical outcomes
of treatment with hypomethylating agents, especially in
terms of risk groups.
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